"Red-Cell Aplasia, Pure" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production.
| Descriptor ID |
D012010
|
| MeSH Number(s) |
C15.378.071.750
|
| Concept/Terms |
Red-Cell Aplasia, Pure- Red-Cell Aplasia, Pure
- Red Cell Aplasia, Pure
- Erythrocyte Aplasia
- Aplasia, Erythrocyte
- Aplasias, Erythrocyte
- Erythrocyte Aplasias
- Pure Red-Cell Aplasia
- Aplasia, Pure Red-Cell
- Aplasias, Pure Red-Cell
- Pure Red Cell Aplasia
- Pure Red-Cell Aplasias
- Red-Cell Aplasias, Pure
|
Below are MeSH descriptors whose meaning is more general than "Red-Cell Aplasia, Pure".
Below are MeSH descriptors whose meaning is more specific than "Red-Cell Aplasia, Pure".
This graph shows the total number of publications written about "Red-Cell Aplasia, Pure" by people in this website by year, and whether "Red-Cell Aplasia, Pure" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 0 | 3 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Red-Cell Aplasia, Pure" by people in Profiles.
-
Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. Am J Ther. 2018 Nov/Dec; 25(6):e670-e674.
-
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med. 2012 Dec; 27(12):1697-703.
-
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008 Aug; 48(8):1754-62.
-
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15; 106(10):3343-7.
-
Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005; 18(3):467-72.
-
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol. 2005; 18(3):481-9.
-
Pure red cell aplasia following pegylated interferon alpha treatment. Am J Med. 2004 Oct 15; 117(8):619-20.
-
Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004 Sep 30; 351(14):1403-8.
-
Significant decrease in hemoglobin and hematocrit levels in a virologically controlled HIV-infected patient. Pure red cell aplasia (PRCA) caused by human parvovirus B19. AIDS Read. 2003 Apr; 13(4):189.
-
Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991 Dec; 302(6):369-73.